No Data
No Data
Austar Lifesciences Prepares for Key Financial Review
Austar (06118.HK) held a board of directors meeting on August 27 to consider and approve its interim performance.
Austar (06118.HK) announced on August 15 that the Board of Directors meeting will be held on Tuesday, August 27, 2024, to consider and approve the unaudited interim performance of the group for the six months ended June 30, 2024, and to consider the declaration of the interim dividend (if any).
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Austar Lifesciences to Swing to Profit in H1
Austar announced profit forecast, with an expected mid-term profit of approximately 3 to 6 million yuan for shareholders.
Austar (06118) announced that it is expected to obtain a profit of approximately RMB 3 million to RMB 6 million attributable to owners of the company for the six months ending June 30, 2024, while the loss attributable to owners of the company for the six months ending June 30, 2023 is approximately RMB 40 million. The expected turnaround from loss to profit is mainly due to: (1) no losses from the indirect non-wholly owned subsidiaries, H+E Pharma GmbH and S-Tec GmbH, of the company at that time, with a loss of approximately RMB 63.9 million for the six months ending June 30, 2023 (-).
Austar Lifesciences Anticipates Profit Turnaround
No Data